Axiom Biosciences Expands Manufacturing and Clinical Development Capabilities Through Partnership with GeneFabStrategic CDMO collaboration strengthens Axiom’s development infrastructure as the company prepares to advance its therapeutic pipeline.
Axiom Biosciences Reports Positive Phase 1 Results for Investigational Stem Cell Therapy in Newborns with Severe Brain InjurySAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences, a clinical-stage biotechnology company developing next-generation regenerative therapies and targeted biologics, today announced positive Phase 1 results for its investigational Wharton’s Jelly-derived mesenchymal stem cell (WJ-MSC) therapy for neonatal brain injury. The therapy, co-developed with South Korea-based Medinno Inc., is being developed to treat intraventricular hemorrhage (IVH) and hypoxic-ischemic encephalopathy (HIE), two severe neurological conditions in newborns associated with high rates of mortality and long-term disability.
Cytonus Therapeutics Becomes Axiom Biosciences, Pairing Its Regenerative Medicine Programs With AI-Enabled Drug DesignSAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences, a clinical-stage biotechnology company developing next-generation regenerative therapies and targeted biologics, today announced its corporate rebranding from Cytonus Therapeutics. The new name reflects the company’s growth from a regenerative medicine innovator into a broader therapeutics company that pairs its clinical-stage cell therapy programs with AI-enabled drug design and targeted delivery technologies.
